Omega promo web banner
Omega promo Mobile banner

Jenburkt Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 524731 | NSE: | Pharmaceuticals & Drugs | Small Cap

Jenburkt Pharma Share Price

1,341.30 -44.40 -3.20%
as on 11-Jul'25 16:59

Jenburkt Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 524731 | NSE: | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Jenburkt Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Jenburkt Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (SA):
18.46
Market Cap:
592 Cr.
52-wk low:
815.8
52-wk high:
1,410

Is Jenburkt Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Jenburkt Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Jenburkt Pharmaceuticals Ltd is a good quality company.

2. Is Jenburkt Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Jenburkt Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Jenburkt Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Jenburkt Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Jenburkt Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Jenburkt Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 40.2%39.3%42%36.9%25.7%23.8%26.9%26.8%26.3%27.9%-
Value Creation
Index
1.91.82.01.60.80.70.90.90.91.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 93.6103115123119109124137142152152
Sales YoY Gr.-10.4%11%7%-3.1%-8.1%13.4%10.3%3.8%6.9%-
Adj EPS 22.928.936.943.231.835.647.954.458.371.972.6
YoY Gr.-26.3%27.7%17%-26.3%11.8%34.5%13.6%7.2%23.2%-
BVPS (₹) 86.4117.1133.5168.8174.3214.6255.8277.3328.4389.2389.2
Adj Net
Profit
10.613.41719.814.616.3222425.731.732
Cash Flow from Ops. 7.81016.2131519.59.317.18.127.9-
Debt/CF from Ops. 0.70.600.60.20.20.60.100.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 5.5%5%7%6.9%
Adj EPS 13.6%17.7%14.5%23.2%
BVPS18.2%17.4%15%18.5%
Share Price 12.8% 28.5% 37% 52.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
28.928.429.328.618.618.320.42019.32018.7
Op. Profit
Mgn %
17.619.120.720.416.618.22222.223.326.626.6
Net Profit
Mgn %
11.41314.816.212.31517.717.618.120.921.1
Debt to
Equity
0.10.100.1000.10000
Working Cap
Days
7165698410112917718515618288
Cash Conv.
Cycle
3837395671624641454268

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 14.49%

Return on Equity has declined versus last 3 years average to 18.70%

Sales growth has been subdued in last 3 years 6.96%

Sales growth is not so good in last 4 quarters at 7.08%

Latest Financials - Jenburkt Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 72.6 -
TTM Sales (₹ Cr.) 152 -
BVPS (₹.) 389.2 -
Reserves (₹ Cr.) 167 -
P/BV 3.45 -
PE 18.46 -
From the Market
52 Week Low / High (₹) 815.80 / 1410.00
All Time Low / High (₹) 1.80 / 1410.00
Market Cap (₹ Cr.) 592
Equity (₹ Cr.) 4.4
Face Value (₹) 10
Industry PE 41.7

Management X-Ray of Jenburkt Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

No data found!

Key Ratios of Jenburkt Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales94103115123119109124137142152
Operating Expenses 77849198998997106109111
Manufacturing Costs5455546776
Material Costs25283133302827292726
Employee Cost 21252831373236394246
Other Costs 25262728282526323334
Operating Profit 16202425202027303340
Operating Profit Margin (%) 17.6%19.1%20.7%20.3%16.6%18.2%22.0%22.2%23.3%26.6%
Other Income 3333445557
Interest 0000100000
Depreciation 2221222223
Exceptional Items 0000000000
Profit Before Tax 17202527212230333544
Tax 67876588912
Profit After Tax 11141720151722252632
PAT Margin (%) 11.5%13.1%15.0%16.1%12.5%15.1%18.0%18.0%18.3%21.1%
Adjusted EPS (₹)23.229.137.543.132.436.048.655.858.972.7
Dividend Payout Ratio (%)31%28%24%24%25%28%25%26%26%25%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 405461778098117122145172
Share Capital 5555555444
Reserves 365057737594113118141167
Minority Interest0000000000
Debt5607346202
Long Term Debt0000000000
Short Term Debt5607346202
Trade Payables3647557668
Others Liabilities 9101211161412101313
Total Liabilities 587678103104120143141164195

Fixed Assets

Gross Block26252627313233343440
Accumulated Depreciation13151617202122242326
Net Fixed Assets12111010121111101015
CWIP 00010001140
Investments 1255478111721
Inventories81171011810899
Trade Receivables691323181415171921
Cash Equivalents 30424152585749547925
Others Assets222222549402965
Total Assets 587678103104120143141164195

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 81016131519917828
PBT 17202527212230333544
Adjustment -1-1-2-2-1-2-2-20-3
Changes in Working Capital -3-31-515-11-6-180
Tax Paid -6-7-8-7-5-6-8-8-8-13
Cash Flow From Investing Activity 0-101-11-3-19-13-1-17
Capex -200-2-4-1-3-2-3-20
Net Investments 032-2-11-2-21-43-4-3
Others 3-4133245265
Cash Flow From Financing Activity -51-18-2-11-1-6-21-7-8
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 0000-100-100
Dividend Paid -30-7-1-90-5-5-6-7
Others -21-11-1-2-1-1-15-1-1
Net Cash Flow 21-10103-103
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)29.2828.5529.7528.5418.8918.4920.6620.5319.4320.25
ROCE (%)40.1739.2641.9936.925.7323.8326.8926.826.2827.85
Asset Turnover Ratio1.61.561.491.361.150.970.940.960.930.84
PAT to CFO Conversion(x)0.730.710.940.6511.120.410.680.310.88
Working Capital Days
Receivable Days25263453635343434748
Inventory Days30332825323126242221
Payable Days516159597165788485101

Jenburkt Pharmaceuticals Ltd Stock News

Jenburkt Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Jenburkt Pharma on 11-Jul-2025 16:59 is ₹1,341.3.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 11-Jul-2025 16:59 the market cap of Jenburkt Pharma stood at ₹592.0.
The latest P/E ratio of Jenburkt Pharma as of 11-Jul-2025 16:59 is 18.46.
The latest P/B ratio of Jenburkt Pharma as of 11-Jul-2025 16:59 is 3.45.
The 52-week high of Jenburkt Pharma is ₹1,410 and the 52-week low is ₹815.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jenburkt Pharma is ₹151.7 ( Cr.) .

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta

Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company, with its stock listed on the Bombay Stock Exchange. Jenburkt's headquarters are ocated in Mumbai, from where it’s entire operations

The company has a state-of-the-art manufacturing plants at Sihor-Gujarat,in India. The plant is modern and well equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical and healthcare products.

The plant is approved as per WHO guidelines for compliances with current GMPrequirements, apart from approvals from various countries.

Jenburkt, has 25 superstockists located in different corners of India, it has approximately 1000 stockists, who buy from Superstockist and sell to chemists. Jenburkt also caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc.

Product range of the company includes: 

Consumer Division:

  • Nocal Tablets
  • Nocal Sachet   
  • Nocal Granular 

Pharmaceutical Division: 

  • Anti-Arthritic
  • Antibiotics 
  • Anti-Diabetic 
  • Nutraceuticals 
  • Anti-Inflammory Analgesics 
  • Gastro Intenstinal 
  • Dermatologicals
  • Aphrodisiac 
  • Anti-Osteoporotic
  • Anti-Cough, Cold & Allergy
  • Anti-Ulcerants

Awards

2010 - The Company was bestowed with "National Award for Excellence in Cost Management-2009" as the "FIRST" awardees under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI), at New Delhi.
2011 - The Company was bestowed with "National Award for Excellence in Cost Management-2010" as the "FIRST"awardee under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI).
The Company has been awarded an NSIC-CRISIL rating of "NSIC-CRISIL SE-1A" on June 30, 2011. The rating indicates ""Highest performance capability and High financial strength".

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...